AUS
NZ
UK
CA
USA
IND
Highlights
- Atria Investments Inc acquired 7,978 shares of Supernus Pharmaceuticals, valued at $288,000.
- Insiders sold 11,104 shares amounting to $440,263 over the past 90 days.
- Supernus Pharmaceuticals focuses on central nervous system treatment products.
During the fourth quarter, Atria Investments Inc took a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), acquiring 7,978 shares valued at approximately $288,000. This move was detailed in a recent disclosure with the Securities and Exchange Commission (SEC). Other institutional investors have also adjusted their holdings, reflecting an active investment phase for the specialty pharmaceutical company. Exchange Traded Concepts LLC increased its position by 2.6% to 22,119 shares, and Rhumbline Advisers expanded its holdings by 0.5%, bringing their total to 172,444 shares. Meanwhile, Quartz Partners LLC and Smartleaf Asset Management LLC also showed increased interest in the company, affirming robust institutional confidence in Supernus Pharmaceuticals' prospects.
Insider Transactions
Significant insider activity was observed as well. Vice President V.P. Padmanabh Bhatt sold 700 shares on January 28th, and Senior Vice President Jonathan Rubin sold 927 shares on February 21st. These transactions resulted in a notable change in insider ownership, with over 11,104 shares sold, valued at approximately $440,263, indicating a strategic realignment among company insiders. Despite these sales, insiders still hold a considerable portion, with ownership accounting for 9.30% of the total shares.
Stock Performance and Company Overview
Supernus Pharmaceuticals' stock opened at $32.16 on Tuesday, with a market capitalization of $1.79 billion. The stock's performance showed a price-to-earnings (P/E) ratio of 30.06 and a beta of 0.83, illustrating relatively moderate volatility compared to the market. The 50-day simple moving average stands at $36.13, while the 200-day average is $35.15. Over the past year, the stock’s range has varied between a low of $25.53 and a high of $40.28. Market analysts provide a spectrum of opinions on the stock, with Cantor Fitzgerald maintaining a "neutral" rating and StockNews.com elevating it to a "strong-buy."
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing products targeting central nervous system (CNS) disorders in the United States. Key offerings include Trokendi XR, an extended-release formulation for epilepsy and migraine prophylaxis, and Oxtellar XR, catering to partial onset seizures in both adults and children. The company's focus on CNS diseases positions it strategically in a specialized segment of the pharmaceutical industry.
